Jennifer G Naples1,2,3, Zachary A Marcum4, Subashan Perera1,5, Shelly L Gray4, Anne B Newman1,6, Eleanor M Simonsick7, Kristine Yaffe8,9,10,11, Ronald I Shorr12, Joseph T Hanlon1,2,3,6. 1. Division of Geriatrics, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. 2. Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania. 3. Center for Health Equity Research and Geriatric Research Education and Clinical Center, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania. 4. School of Pharmacy, University of Washington, Seattle, Washington. 5. Department of Biostatistics, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania. 6. Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania. 7. Intramural Research Program, National Institute on Aging, Baltimore, Maryland. 8. Department of Psychiatry, University of California at San Francisco, San Francisco, California. 9. Department of Neurology, University of California at San Francisco, San Francisco, California. 10. Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, California. 11. San Francisco Veterans Affairs Medical Center, San Francisco, California. 12. Geriatric Research, Education and Clinical Center, Malcolm Randall Veterans Affairs Medical Center, Gainesville, Florida.
Abstract
OBJECTIVES: To evaluate concordance of five commonly used anticholinergic scales. DESIGN: Cross-sectional secondary analysis. SETTING: Pittsburgh, Pennsylvania, and Memphis, Tennessee. PARTICIPANTS: Community-dwelling adults aged 70 to 79 with baseline medication data from the Health, Aging, and Body Composition Study (N = 3,055). MEASUREMENTS: Any anticholinergic use, weighted scores, and total standardized daily dosage were calculated using five anticholinergic measures (Anticholinergic Cognitive Burden (ACB) Scale, Anticholinergic Drug Scale (ADS), Anticholinergic Risk Scale (ARS), Drug Burden Index anticholinergic component (DBI-ACh), and Summated Anticholinergic Medications Scale (SAMS)). Concordance was evaluated using kappa statistics and Spearman rank correlations. RESULTS: Any anticholinergic use in rank order was 51% for the ACB, 43% for the ADS, 29% for the DBI-ACh, 23% for the ARS, and 16% for the SAMS. Kappa statistics for all pairwise use comparisons ranged from 0.33 to 0.68. Similarly, concordance as measured using weighted kappa statistics ranged from 0.54 to 0.70 for the three scales not incorporating dosage (ADS, ARS, ACB). Spearman rank correlation between the DBI-ACh and SAMS was 0.50. CONCLUSION: Only low to moderate concordance was found between the five anticholinergic scales. Future research is needed to examine how these differences in measurement affect their predictive validity with respect to clinically relevant outcomes, such as cognitive impairment.
OBJECTIVES: To evaluate concordance of five commonly used anticholinergic scales. DESIGN: Cross-sectional secondary analysis. SETTING: Pittsburgh, Pennsylvania, and Memphis, Tennessee. PARTICIPANTS: Community-dwelling adults aged 70 to 79 with baseline medication data from the Health, Aging, and Body Composition Study (N = 3,055). MEASUREMENTS: Any anticholinergic use, weighted scores, and total standardized daily dosage were calculated using five anticholinergic measures (Anticholinergic Cognitive Burden (ACB) Scale, Anticholinergic Drug Scale (ADS), Anticholinergic Risk Scale (ARS), Drug Burden Index anticholinergic component (DBI-ACh), and Summated Anticholinergic Medications Scale (SAMS)). Concordance was evaluated using kappa statistics and Spearman rank correlations. RESULTS: Any anticholinergic use in rank order was 51% for the ACB, 43% for the ADS, 29% for the DBI-ACh, 23% for the ARS, and 16% for the SAMS. Kappa statistics for all pairwise use comparisons ranged from 0.33 to 0.68. Similarly, concordance as measured using weighted kappa statistics ranged from 0.54 to 0.70 for the three scales not incorporating dosage (ADS, ARS, ACB). Spearman rank correlation between the DBI-ACh and SAMS was 0.50. CONCLUSION: Only low to moderate concordance was found between the five anticholinergic scales. Future research is needed to examine how these differences in measurement affect their predictive validity with respect to clinically relevant outcomes, such as cognitive impairment.
Authors: Shelly L Gray; Melissa L Anderson; Sascha Dublin; Joseph T Hanlon; Rebecca Hubbard; Rod Walker; Onchee Yu; Paul K Crane; Eric B Larson Journal: JAMA Intern Med Date: 2015-03 Impact factor: 21.873
Authors: Sarah N Hilmer; Donald E Mager; Eleanor M Simonsick; Ying Cao; Shari M Ling; B Gwen Windham; Tamara B Harris; Joseph T Hanlon; Susan M Rubin; Ronald I Shorr; Douglas C Bauer; Darrell R Abernethy Journal: Arch Intern Med Date: 2007-04-23
Authors: Anne B Newman; Catherine L Haggerty; Stephen B Kritchevsky; Michael C Nevitt; Eleanor M Simonsick Journal: J Gerontol A Biol Sci Med Sci Date: 2003-08 Impact factor: 6.053
Authors: Matthew S Duprey; John W Devlin; Becky A Briesacher; Thomas G Travison; John L Griffith; Sharon K Inouye Journal: J Am Geriatr Soc Date: 2020-10-01 Impact factor: 5.562
Authors: Zachary A Marcum; Heidi S Wirtz; Mary Pettinger; Andrea Z LaCroix; Ryan Carnahan; Jane A Cauley; Jennifer W Bea; Shelly L Gray Journal: Drugs Aging Date: 2015-09 Impact factor: 3.923
Authors: Marta Lavrador; Ana C Cabral; Isabel V Figueiredo; Manuel T Veríssimo; M Margarida Castel-Branco; Fernando Fernandez-Llimos Journal: Int J Clin Pharm Date: 2020-08-29